FY2025 EPS Estimates for Alkermes Cut by Leerink Partnrs

Alkermes plc (NASDAQ:ALKS) – Equities researchers at Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for Alkermes in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of $1.50 per share for the year, down from their previous estimate of $1.55. The consensus estimate for Alkermes’ current full-year earnings is $2.23 per share. Leerink Partnrs also issued estimates for Alkermes’ FY2026 earnings at $1.84 EPS.

A number of other analysts have also recently issued reports on ALKS. Piper Sandler reissued an “overweight” rating and issued a $37.00 price objective (down from $38.00) on shares of Alkermes in a research note on Friday, October 25th. The Goldman Sachs Group cut their price target on Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Mizuho boosted their price objective on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. dropped their price objective on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Finally, HC Wainwright reissued a “neutral” rating and set a $37.00 target price on shares of Alkermes in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Alkermes has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Alkermes Stock Up 1.0 %

NASDAQ ALKS opened at $31.56 on Thursday. The stock’s 50-day moving average price is $29.66 and its 200-day moving average price is $28.22. The company has a market capitalization of $5.11 billion, a P/E ratio of 16.18, a price-to-earnings-growth ratio of 1.56 and a beta of 0.49. Alkermes has a 52 week low of $22.90 and a 52 week high of $32.88. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22.

Insider Buying and Selling

In other Alkermes news, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the sale, the director now owns 23,013 shares in the company, valued at $732,964.05. This trade represents a 10.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Craig C. Hopkinson sold 58,996 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.08, for a total transaction of $1,774,599.68. Following the sale, the executive vice president now directly owns 83,300 shares of the company’s stock, valued at $2,505,664. This represents a 41.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 147,738 shares of company stock valued at $4,572,904. Insiders own 4.89% of the company’s stock.

Hedge Funds Weigh In On Alkermes

A number of institutional investors have recently modified their holdings of the stock. V Square Quantitative Management LLC purchased a new stake in shares of Alkermes in the third quarter valued at approximately $29,000. Blue Trust Inc. raised its position in Alkermes by 2,394.5% during the 4th quarter. Blue Trust Inc. now owns 1,821 shares of the company’s stock valued at $51,000 after purchasing an additional 1,748 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Alkermes by 83.8% in the 3rd quarter. GAMMA Investing LLC now owns 4,204 shares of the company’s stock worth $118,000 after buying an additional 1,917 shares during the period. Archer Investment Corp grew its position in shares of Alkermes by 28.6% during the 3rd quarter. Archer Investment Corp now owns 4,500 shares of the company’s stock worth $126,000 after buying an additional 1,000 shares in the last quarter. Finally, KBC Group NV grew its position in shares of Alkermes by 18.8% during the 3rd quarter. KBC Group NV now owns 4,890 shares of the company’s stock worth $137,000 after buying an additional 774 shares in the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.